Spores have long been a source of significant health challenges and in recent decades these challenges have increased. Among these challenges, infection resulting from the spore, Clostridium difficile (CDI) has reached "superbug" status as a hospital-borne infection. The spores act as Trojan horses. They remain dormant until they reach a hospitable host where they germinate and cause havoc.
At Able Therapeutics, we are applying quantitative approaches to
microbiological problems. This enables us to develop techniques for evaluating the mechanisms of Clostridium spore germination, which are at the heart of some of today's most significant unmet health challenges. With this information we are then able to design and synthesize spore germination inhibitors that serve as prophylactic agents against bacterial infections.
We leverage expertise in bioorganic chemistry, medicinal chemistry, enzymology, animal model of infections, microbiology, and bacterial spore germination. Our scientific team has been working with bacterial spores for more than ten years and have produced numerous papers in the area. The eclectic mixture of techniques used in our laboratory have proven crucial to advancing developing of compounds that address health challenges in the marketplace.
SOLUTIONS FOR UNMET NEEDS
LEVERAGING CROSS-DISCIPLINARY SCIENCE TO ADDRESS HEALTH CHALLENGES CREATIVELY
PARTNERING WITH EXPERTS
TOGETHER WE ACHIEVE MORE, FASTER, WITH POWERFUL RESULTS